Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Hiroaki Baba; Hajime Kanamori; Kengo Oshima; Issei Seike; Ikumi Niitsuma-Sugaya; Kentaro Takei; Yukio Sato; Koichi Tokuda; Tetsuji Aoyagi

doi:10.1016/j.jiac.2020.06.022

Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Hiroaki Baba, Hajime Kanamori, Kengo Oshima, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Yukio Sato, Koichi Tokuda, Tetsuji Aoyagi

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

Original language	English
Pages (from-to)	1100-1103
Number of pages	4
Journal	Journal of Infection and Chemotherapy
Volume	26
Issue number	10
DOIs	https://doi.org/10.1016/j.jiac.2020.06.022
Publication status	Published - 2020 Oct

Keywords

Ciclesonide
Coronavirus disease 2019
Iguratimod
Viral shedding

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jiac.2020.06.022

Cite this

@article{577718db44a8422b86f8df0e1cef826b,

title = "Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide",

abstract = "We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.",

keywords = "Ciclesonide, Coronavirus disease 2019, Iguratimod, Viral shedding",

author = "Hiroaki Baba and Hajime Kanamori and Kengo Oshima and Issei Seike and Ikumi Niitsuma-Sugaya and Kentaro Takei and Yukio Sato and Koichi Tokuda and Tetsuji Aoyagi",

note = "Publisher Copyright: {\textcopyright} 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases",

year = "2020",

month = oct,

doi = "10.1016/j.jiac.2020.06.022",

language = "English",

volume = "26",

pages = "1100--1103",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "10",

}

TY - JOUR

T1 - Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

AU - Baba, Hiroaki

AU - Kanamori, Hajime

AU - Oshima, Kengo

AU - Seike, Issei

AU - Niitsuma-Sugaya, Ikumi

AU - Takei, Kentaro

AU - Sato, Yukio

AU - Tokuda, Koichi

AU - Aoyagi, Tetsuji

PY - 2020/10

Y1 - 2020/10

N2 - We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

AB - We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

KW - Ciclesonide

KW - Coronavirus disease 2019

KW - Iguratimod

KW - Viral shedding

UR - http://www.scopus.com/inward/record.url?scp=85087397991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087397991&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2020.06.022

DO - 10.1016/j.jiac.2020.06.022

M3 - Article

C2 - 32631736

AN - SCOPUS:85087397991

SN - 1341-321X

VL - 26

SP - 1100

EP - 1103

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 10

ER -

Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this